Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 9:24 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2137–2160 of 33,158 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: PLACEBO Clear all

Conditions: COVID-19
Interventions: Clazakizumab; Drug
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Atopic Dermatitis, Atopic Hand Eczema
Interventions: Tralokinumab, Placebo; Drug
Lead sponsor: LEO Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 235 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 23
States / cities: Birmingham, Alabama • Fort Smith, Arkansas • Fountain Valley, California + 19 more

Conditions: Schizophrenia
Interventions: NaBen®, Placebo; Drug
Lead sponsor: SyneuRx International (Taiwan) Corp; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2023
U.S. locations: 20
States / cities: Dothan, Alabama • Bellflower, California • Long Beach, California + 17 more

Conditions: Healthy Volunteer - Complete, Cystic Fibrosis - Complete
Interventions: PTI-808, Placebo, PTI-428, PTI-801; Drug
Lead sponsor: Proteostasis Therapeutics, Inc.; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 179 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 22
States / cities: Tucson, Arizona • Stanford, California • Denver, Colorado + 18 more

Conditions: Fibromyalgia, Migraine
Interventions: zonisamide; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Parkinson Disease, Multiple System Atrophy, Autonomic Nervous System Diseases
Interventions: Droxidopa, Carbidopa, Entacapone; Drug
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Post Traumatic Stress Disorder
Interventions: Bupivacaine, Saline; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 65 Years
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Anorexia Nervosa, Osteopenia, Osteoporosis
Interventions: rhIGF-1, Risedronate, Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Myasthenia Gravis
Interventions: Ublituximab, Placebo; Drug
Lead sponsor: TG Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 7
States / cities: Colorado Springs, Colorado • Clearwater, Florida • Maitland, Florida + 3 more

Conditions: Knee Osteoarthritis
Interventions: Blinded study medication; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 45 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Visual Perception, Attention, Information Processing, Cholinergic System
Interventions: Donepzil, Placebo oral tablet; Drug
Lead sponsor: University of California, Berkeley; Other
Eligibility: 18 Years to 80 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Berkeley, California

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: anamorelin HCl, placebo; Drug
Lead sponsor: Helsinn Therapeutics (U.S.), Inc; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 228 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 19
States / cities: Little Rock, Arkansas • Melbourne, Florida • Augusta, Georgia + 12 more

Conditions: Staphylococcal Infection
Interventions: Placebo, XF-73 in 2% Klucel gel, XF-73 in 4% Klucel gel; Other · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 2
States / cities: Anaheim, California • Cleveland, Ohio

Conditions: Aneurysmal Subarachnoid Hemorrhage
Interventions: Clazosentan, Placebo; Drug
Lead sponsor: Idorsia Pharmaceuticals Ltd.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,157 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 11
States / cities: Phoenix, Arizona • Englewood, Colorado • Boston, Massachusetts + 8 more

Conditions: Alopecia
Interventions: Setipiprant, Placebo, Finasteride; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years to 49 Years · Male only
Enrollment: 169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 18
States / cities: Hot Springs, Arkansas • Little Rock, Arkansas • San Diego, California + 14 more

Conditions: Heart Defects, Congenital
Interventions: nesiritide, milrinone, placebo; Drug
Lead sponsor: John M Costello; Other
Eligibility: Not listed
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Constipation
Interventions: Lubiprostone, Senna; Drug
Lead sponsor: Shirley Ryan AbilityLab; Other
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Sleep, Anxiety, Depression, Pain
Interventions: fsCBD Cannabidiol, bsCBD Cannabidiol, Placebo; Drug
Lead sponsor: University of Colorado, Boulder; Other
Eligibility: 60 Years and older
Enrollment: 385 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Boulder, Colorado

Conditions: Chronic Kidney Disease
Interventions: Finerenone (BAY94-8862), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 5,734 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 176
States / cities: Birmingham, Alabama • Fort Payne, Alabama • Huntsville, Alabama + 125 more

Conditions: Shoulder Arthroplasty
Interventions: oral tranexamic acid, Placebo; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 79 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Dental Pain
Interventions: Acetaminophen ER, Placebo; Drug
Lead sponsor: McNeil Consumer Healthcare Division of McNEIL-PPC, Inc.; Industry
Eligibility: 17 Years to 45 Years
Enrollment: 403 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Respiratory Infection, Elderly
Interventions: Vitamin E; Dietary Supplement
Lead sponsor: Tufts University; Other
Eligibility: 65 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 1997
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Gastroesophageal Reflux Disease
Interventions: arbaclofen placarbil-Cohort 1, Placebo-Cohort 5, arbaclofen placarbil-Cohort 2, arbaclofen placarbil-Cohort 3, arbaclofen placarbil-Cohort 4, PPI; Drug
Lead sponsor: XenoPort, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 460 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 62
States / cities: Huntsville, Alabama • Chandler, Arizona • Mesa, Arizona + 56 more

Conditions: HIV Infections
Interventions: VSV-Indiana HIV gag vaccine, Placebo injection (normal saline); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2011
U.S. locations: 4
States / cities: San Francisco, California • Decatur, Georgia • Philadelphia, Pennsylvania + 1 more

Search by objective public record fields.

Clazakizumab (Anti-Interleukin 6 (IL-6) Monoclonal) Compared to Placebo for Coronavirus Disease 2019 (COVID-19)

A 32-week Trial to Evaluate the Efficacy and Safety of Tralokinumab in Subjects With Moderate-to-severe Atopic Hand Eczema Who Are Candidates for Systemic Therapy

Adaptive Phase II Study to Evaluate the Safety & Efficacy of NaBen®

Study Designed to Assess the Safety, Tolerability and PK of PTI-808 in Healthy Volunteers and in Adults With Cystic Fibrosis

Zonisamide for Fibromyalgia & Migraine

Augmenting Effects of L-DOPS With Carbidopa and Entacapone

Effects of Stellate Ganglion Block in Post-traumatic Stress Disorder

IGF-1 and Bone Loss in Women With Anorexia Nervosa

A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG)

Maximizing Analgesia to Reduce Pain in Knee Osteoarthritis

Effects of Acetylcholine and Attention on Visual Spatial Representations in the Brain

Dose Range Study of Anamorelin in Patients With Non-small Cell Lung Cancer

Study of the Safety and Local Tolerability of Intranasal Gel Formulations of XF-73

Clazosentan in Reducing Vasospasm-related Morbidity and All-cause Mortality in Adult Patients With Aneurysmal Subarachnoid Hemorrhage Treated by Surgical Clipping

A Safety and Efficacy Study of Setipiprant Tablets in Androgenetic Alopecia in Males

Effects of Perioperative Nesiritide or Milrinone Infusion on Recovery From Fontan Surgery

Lubiprostone (Amitiza®) Vs. Standard Care in Opioid-induced Constipation After Surgery in Inpatient Rehabilitation

Cannabidiol and Older Adult Cannabis Users

Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease

Effects of Oral Tranexamic Acid on Short Term Postoperative Outcomes Following Total Shoulder Arthroplasty

Study of Long-Acting Acetaminophen in Postoperative Dental Pain

Vitamin E and Infection in the Elderly

A Study to Evaluate the Efficacy and Safety of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD)

Evaluating the Safety of and Immune Response to the VSV-Indiana HIV Vaccine in Healthy, HIV-Uninfected Adults